Page 51 - MI-2-1

Microbes & Immunity iPSC-derived NK cell immunotherapy

121. Moreno-Nieves UY, Mundy DC, Shin JH, Tam K, 132. Shi Y, Riese DJ 2 , Shen J. The role of the CXCL12/CXCR4/
nd
Sunwoo JB. The aryl hydrocarbon receptor modulates CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;
the function of human CD56 bright NK cells. Eur J Immunol. 11:574667.
2018;48(5):771-776. doi: 10.3389/fphar.2020.574667
doi: 10.1002/eji.201747289 133. Muller N, Michen S, Tietze S, et al. Engineering NK cells
122. Zhang LH, Shin JH, Haggadone MD, Sunwoo JB. The aryl modified with an EGFRvIII-specific chimeric antigen
hydrocarbon receptor is required for the maintenance of liver- receptor to overexpress CXCR4 improves immunotherapy of
resident natural killer cells. J Exp Med. 2016;213(11):2249-2257. CXCL12/SDF-1alpha-secreting glioblastoma. J Immunother.
2015;38(5):197-210.
doi: 10.1084/jem.20151998
doi: 10.1097/CJI.0000000000000082
123. Galley HF, Lowe PR, Carmichael RL, Webster NR. Genotype
and interleukin-10 responses after cardiopulmonary bypass. 134. Wirthmueller U, Kurosaki T, Murakami MS, Ravetch JV.
Br J Anaesth. 2003;91(3):424-426. Signal transduction by Fc gamma RIII (CD16) is mediated
through the gamma chain. J Exp Med. 1992;175(5):1381-1390.
doi: 10.1093/bja/aeg174
doi: 10.1084/jem.175.5.1381
124. Wagage S, John B, Krock BL, et al. The aryl hydrocarbon
receptor promotes IL-10 production by NK cells. J Immunol. 135. Barry WE, Jackson JR, Asuelime GE, et al. Activated
2014;192(4):1661-1670. natural killer cells in combination with anti-GD2 antibody
dinutuximab improve survival of mice after surgical
doi: 10.4049/jimmunol.1300497 resection of primary neuroblastoma. Clin Cancer Res.
125. Scoville SD, Nalin AP, Chen L, et al. Human AML activates 2019;25(1):325-333.
the aryl hydrocarbon receptor pathway to impair NK cell doi: 10.1158/1078-0432.CCR-18-1317
development and function. Blood. 2018;132(17):1792-1804.
136. Modak S, Le Luduec JB, Cheung IY, et al. Adoptive
doi: 10.1182/blood-2018-03-838474 immunotherapy with haploidentical natural killer cells
126. Gabriely G, Wheeler MA, Takenaka MC, Quintana FJ. Role and Anti-GD2 monoclonal antibody m3F8 for resistant
of AHR and HIF-1alpha in glioblastoma metabolism. Trends neuroblastoma: Results of a phase I study. Oncoimmunology.
Endocrinol Metab. 2017;28(6):428-436. 2018;7(8):e1461305.
doi: 10.1016/j.tem.2017.02.009 doi: 10.1080/2162402X.2018.1461305
127. Daussy C, Faure F, Mayol K, et al. T-bet and Eomes 137. Zhu H, Blum RH, Bjordahl R, et al. Pluripotent stem
instruct the development of two distinct natural killer cell cell-derived NK cells with high-affinity noncleavable
lineages in the liver and in the bone marrow. J Exp Med. CD16a mediate improved antitumor activity. Blood.
2014;211(3):563-577. 2020;135(6):399-410.
doi: 10.1084/jem.20131560 doi: 10.1182/blood.2019000621
128. Zhang J, Marotel M, Fauteux-Daniel S, et al. T-bet and eomes 138. Pattali R, Izzo K, Goncz E, et al. 191 GAPDH knock-in
govern differentiation and function of mouse and human NK of high affinity CD16 in iPSC derived NK cells drives
cells and ILC1. Eur J Immunol. 2018;48(5):738-750. high-level expression and increased anti-tumor function.
J Immunother Cancer. 2021;9(Suppl 2):A203.
doi: 10.1002/eji.201747299
doi: 10.1136/jitc-2021-SITC2021.191
129. Kiekens L, Van Loocke W, Taveirne S, et al. T-BET and
EOMES accelerate and enhance functional differentiation of 139. Hullsiek R, Li Y, Snyder KM, et al. Examination of IgG Fc
human natural killer cells. Front Immunol. 2021;12:732511. receptor CD16A and CD64 expression by canine leukocytes
and their ADCC activity in engineered NK cells. Front
doi: 10.3389/fimmu.2021.732511 Immunol. 2022;13:841859.
130. Kremer V, Ligtenberg MA, Zendehdel R, et al. Genetic doi: 10.3389/fimmu.2022.841859
engineering of human NK cells to express CXCR2 improves
migration to renal cell carcinoma. J Immunother Cancer. 140. Snyder KM, Hullsiek R, Mishra HK, et al. Expression of a
recombinant high affinity IgG Fc receptor by engineered NK
2017;5(1):73.
cells as a docking platform for therapeutic mAbs to target
doi: 10.1186/s40425-017-0275-9 cancer cells. Front Immunol. 2018;9:2873.
131. Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 doi: 10.3389/fimmu.2018.02873
in cell proliferation and tissue regeneration. Front Immunol. 141. Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage
2020;11:2109.
region in human CD16 (FcγRIII) and the engineering of a
doi: 10.3389/fimmu.2020.02109 non-cleavable version of the receptor in NK cells. PLoS One.

Volume 2 Issue 1 (2025) 43 doi: 10.36922/mi.5653